Abstract

This project is designed to prepare a GMP quality investigational alternative serotypes (other than Ad5) HIV vaccine and complete the preclinical and laboratory studies needed to begin a clinical trial. The first clinical trial is a Phase I study to examine tolerability, dose, and immune response of the HIV vaccine. The hypothesis is that this vaccine will be safe for human administration and elicit immune responses to HIV. Clinical materials have been manufactured in compliance with current Good Manufacturing Practices (cGMP) and released for use in Phase I clinical trials

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Production Facilities Intramural Research (ZIB)
Project #
1ZIBAI005074-07
Application #
8336673
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
2011
Total Cost
$1,159,913
Indirect Cost

  Institution

Name
National Institute of Allergy and Infectious Diseases
Department
Type
DUNS #
City
State
Country
Zip Code